Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 5.22
CORT's Cash-to-Debt is ranked lower than
61% of the 983 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CORT: 5.22 )
Ranked among companies with meaningful Cash-to-Debt only.
CORT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.72  Med: 662.47 Max: No Debt
Current: 5.22
Equity-to-Asset 0.66
CORT's Equity-to-Asset is ranked lower than
52% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CORT: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
CORT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.1  Med: 0.58 Max: 0.89
Current: 0.66
-0.1
0.89
Interest Coverage 8.67
CORT's Interest Coverage is ranked lower than
87% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CORT: 8.67 )
Ranked among companies with meaningful Interest Coverage only.
CORT' s Interest Coverage Range Over the Past 10 Years
Min: 4.99  Med: N/A Max: No Debt
Current: 8.67
Piotroski F-Score: 8
Altman Z-Score: 29.64
Beneish M-Score: -1.76
WACC vs ROIC
11.84%
293.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 15.43
CORT's Operating Margin % is ranked higher than
84% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CORT: 15.43 )
Ranked among companies with meaningful Operating Margin % only.
CORT' s Operating Margin % Range Over the Past 10 Years
Min: -69827.59  Med: -748.74 Max: 12.52
Current: 15.43
-69827.59
12.52
Net Margin % 13.51
CORT's Net Margin % is ranked higher than
85% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. CORT: 13.51 )
Ranked among companies with meaningful Net Margin % only.
CORT' s Net Margin % Range Over the Past 10 Years
Min: -69537.93  Med: -797.39 Max: 10.01
Current: 13.51
-69537.93
10.01
ROE % 37.33
CORT's ROE % is ranked higher than
97% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CORT: 37.33 )
Ranked among companies with meaningful ROE % only.
CORT' s ROE % Range Over the Past 10 Years
Min: -356.04  Med: -110.44 Max: 27.19
Current: 37.33
-356.04
27.19
ROA % 19.80
CORT's ROA % is ranked higher than
97% of the 992 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. CORT: 19.80 )
Ranked among companies with meaningful ROA % only.
CORT' s ROA % Range Over the Past 10 Years
Min: -106.94  Med: -73.98 Max: 13.49
Current: 19.8
-106.94
13.49
ROC (Joel Greenblatt) % 848.45
CORT's ROC (Joel Greenblatt) % is ranked higher than
98% of the 952 Companies
in the Global Biotechnology industry.

( Industry Median: -369.38 vs. CORT: 848.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CORT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -370585.71  Med: -40045.6 Max: 464.79
Current: 848.45
-370585.71
464.79
3-Year Revenue Growth Rate 88.80
CORT's 3-Year Revenue Growth Rate is ranked higher than
94% of the 528 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CORT: 88.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CORT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 230.2
Current: 88.8
0
230.2
GuruFocus has detected 2 Warning Signs with Corcept Therapeutics Inc $CORT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CORT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NYSE:EBS, NAS:INVA, NAS:RGEN, NAS:FOLD, NAS:XLRN, NAS:DERM, NAS:GBT, NAS:ARRY, NAS:OMER, NAS:INSM » details
Traded in other countries:HTD.Germany,
Headquarter Location:USA
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Corcept Therapeutics Inc was incorporated in the State of Delaware on May 13, 1998. The Company is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric and oncologic disorders. The Company focuses on disorders associated with the steroid hormone cortisol. The company focuses on commercializing Korlym 300 mg Tablet, a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome, who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It is also conducting a Phase III clinical study for mifepristone, the active ingredient in Korlym, for the treatment of psychotic depression; and developing CORT 108297, a novel glucocorticoid receptor II antagonist in Phase 1b/2a clinical trial. The Company has research and development agreement with Argenta Discovery Limited; Sygnature Discovery Limited; ICON Clinical Research, L.P.; and MedAvante, Inc. as well as has a patent license from Stanford University for developing mifepristone.

Top Ranked Articles about Corcept Therapeutics Inc

Corcept Therapeutics Appoints Renee D. Gala to Board of Directors

MENLO PARK, CA--(Marketwired - Jun 28, 2016) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of the stress hormone cortisol, announced today that Renée D. Galá has joined the company's Board of Directors. "I am very pleased to welcome Renée to our Board," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Her broad financial and operating experience will be invaluable as we continue to grow our Cushing's syndrome business and advance our portfolio of cortisol-modulating compounds for new indications." Ms. Galá is the Senior Vice President and Chief Financial Officer of Theravance Biopharma, a public biopharmaceutical company focused on anti-infectives and diseases of the lung and gastrointestinal tract. In that role, she is responsible for finance, accounting, tax, investor relations, information technology, facilities and corporate business development. Ms. Galá joined Theravance, Inc. in 2006 and held various roles in the finance organization before leading the separation of the biopharmaceutical business (now Theravance Biopharma) from the royalty company (Innoviva, Inc.) in 2014. Prior to joining Theravance, Inc., Ms. Galá held positions of increasing responsibility in global treasury, pharmaceutical sales, and corporate strategy/business development at Eli Lilly and Company. Before that, she worked for seven years in the energy industry, both in the United States and internationally, in positions focused on corporate finance, project finance and mergers and acquisitions. Ms. Galá holds a B.S. in Mathematics from Vanderbilt University and an M.B.A. from Columbia Business School. "I am excited to join the Corcept team," said Ms. Galá. "The company's Cushing's syndrome franchise is a promising stand-alone business that also supports development of cortisol modulators with demonstrated therapeutic potential. In the next 12-18 months, research conducted by Corcept and its academic collaborators will generate efficacy data in a wide range of serious disorders. I am looking forward to contributing to the advancement of such a broad and rich therapeutic platform." About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that selectively modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone (the active ingredient in Korlym), in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators. Forward-Looking Statements
Statements made in this press release, other than statements of historical fact, are forward-looking statements. These forward-looking statements, including statements regarding the timing of clinical trial results and the advancement of the company's therapeutic platform, are subject to known and unknown risks and uncertainties that might cause actual results to differ materially from those expressed or implied by such statements, including the pace of Korlym's acceptance by physicians and patients, the pace of enrollment in or the outcome of Corcept's Phase 1/2 study of mifepristone in the treatment of triple-negative breast cancer, CORT125134 to treat solid-tumor cancers and clinical trials being undertaken by academic investigators at the University of Chicago and elsewhere, the pre-clinical development of Corcept's selective cortisol modulators, the effects of rapid technological change and competition, the protections afforded by Korlym's Orphan Drug designation or Corcept's intellectual property rights, or the cost, pace and success of Corcept's other product development efforts. These and other risks are set forth in the company's SEC filings, which are available at the company's website (corcept.com) or from the SEC's website (sec.gov). Corcept disclaims any intention or duty to update any forward-looking statement made in this press release.


CONTACT:

Charles Robb

Chief Financial Officer

Corcept Therapeutics

650-688-8783

Email Contact

www.corcept.com





Read more...

Ratios

vs
industry
vs
history
PE Ratio 113.91
CORT's PE Ratio is ranked lower than
84% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 30.85 vs. CORT: 113.91 )
Ranked among companies with meaningful PE Ratio only.
CORT' s PE Ratio Range Over the Past 10 Years
Min: 82.82  Med: 119 Max: 601
Current: 113.91
82.82
601
PE Ratio without NRI 113.91
CORT's PE Ratio without NRI is ranked lower than
84% of the 237 Companies
in the Global Biotechnology industry.

( Industry Median: 31.14 vs. CORT: 113.91 )
Ranked among companies with meaningful PE Ratio without NRI only.
CORT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 82.82  Med: 119 Max: 601
Current: 113.91
82.82
601
Price-to-Owner-Earnings 103.55
CORT's Price-to-Owner-Earnings is ranked lower than
85% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 35.17 vs. CORT: 103.55 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
CORT' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 68.08  Med: 100.28 Max: 667.78
Current: 103.55
68.08
667.78
PB Ratio 28.61
CORT's PB Ratio is ranked lower than
95% of the 888 Companies
in the Global Biotechnology industry.

( Industry Median: 3.78 vs. CORT: 28.61 )
Ranked among companies with meaningful PB Ratio only.
CORT' s PB Ratio Range Over the Past 10 Years
Min: 1.82  Med: 14.62 Max: 86.18
Current: 28.61
1.82
86.18
PS Ratio 15.94
CORT's PS Ratio is ranked lower than
54% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.91 vs. CORT: 15.94 )
Ranked among companies with meaningful PS Ratio only.
CORT' s PS Ratio Range Over the Past 10 Years
Min: 7.23  Med: 128.54 Max: 1990
Current: 15.94
7.23
1990
Price-to-Free-Cash-Flow 60.83
CORT's Price-to-Free-Cash-Flow is ranked lower than
76% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 27.50 vs. CORT: 60.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CORT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 33.61  Med: 58 Max: 195.93
Current: 60.83
33.61
195.93
Price-to-Operating-Cash-Flow 60.24
CORT's Price-to-Operating-Cash-Flow is ranked lower than
80% of the 181 Companies
in the Global Biotechnology industry.

( Industry Median: 24.15 vs. CORT: 60.24 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CORT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 33.4  Med: 57.77 Max: 188.93
Current: 60.24
33.4
188.93
EV-to-EBIT 96.01
CORT's EV-to-EBIT is ranked lower than
89% of the 262 Companies
in the Global Biotechnology industry.

( Industry Median: 22.66 vs. CORT: 96.01 )
Ranked among companies with meaningful EV-to-EBIT only.
CORT' s EV-to-EBIT Range Over the Past 10 Years
Min: -164.1  Med: -5.65 Max: 488.9
Current: 96.01
-164.1
488.9
EV-to-EBITDA 95.53
CORT's EV-to-EBITDA is ranked lower than
91% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.28 vs. CORT: 95.53 )
Ranked among companies with meaningful EV-to-EBITDA only.
CORT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -171.8  Med: -5.7 Max: 436.4
Current: 95.53
-171.8
436.4
Current Ratio 2.59
CORT's Current Ratio is ranked lower than
66% of the 977 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CORT: 2.59 )
Ranked among companies with meaningful Current Ratio only.
CORT' s Current Ratio Range Over the Past 10 Years
Min: 1.89  Med: 6.88 Max: 37.77
Current: 2.59
1.89
37.77
Quick Ratio 2.48
CORT's Quick Ratio is ranked lower than
64% of the 976 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CORT: 2.48 )
Ranked among companies with meaningful Quick Ratio only.
CORT' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 6.88 Max: 37.77
Current: 2.48
1.81
37.77
Days Inventory 367.70
CORT's Days Inventory is ranked lower than
88% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CORT: 367.70 )
Ranked among companies with meaningful Days Inventory only.
CORT' s Days Inventory Range Over the Past 10 Years
Min: 355.69  Med: 476.53 Max: 2487.36
Current: 367.7
355.69
2487.36
Days Sales Outstanding 36.22
CORT's Days Sales Outstanding is ranked higher than
74% of the 627 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. CORT: 36.22 )
Ranked among companies with meaningful Days Sales Outstanding only.
CORT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.26  Med: 45.83 Max: 61.48
Current: 36.22
44.26
61.48
Days Payable 674.64
CORT's Days Payable is ranked higher than
97% of the 433 Companies
in the Global Biotechnology industry.

( Industry Median: 55.32 vs. CORT: 674.64 )
Ranked among companies with meaningful Days Payable only.
CORT' s Days Payable Range Over the Past 10 Years
Min: 355.35  Med: 780.49 Max: 15257.8
Current: 674.64
355.35
15257.8

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.10
CORT's 3-Year Average Share Buyback Ratio is ranked higher than
76% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: -11.90 vs. CORT: -4.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CORT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -61.6  Med: -20.3 Max: -3.2
Current: -4.1
-61.6
-3.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 52.21
CORT's Price-to-Net-Cash is ranked lower than
92% of the 532 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. CORT: 52.21 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CORT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.5  Med: 6.38 Max: 376
Current: 52.21
2.5
376
Price-to-Net-Current-Asset-Value 34.80
CORT's Price-to-Net-Current-Asset-Value is ranked lower than
89% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 7.00 vs. CORT: 34.80 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CORT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.43  Med: 6.37 Max: 93.33
Current: 34.8
2.43
93.33
Price-to-Tangible-Book 28.61
CORT's Price-to-Tangible-Book is ranked lower than
93% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. CORT: 28.61 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CORT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.31  Med: 6.58 Max: 82.35
Current: 28.61
2.31
82.35
Price-to-Median-PS-Value 0.13
CORT's Price-to-Median-PS-Value is ranked higher than
97% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CORT: 0.13 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CORT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 0.31 Max: 9.92
Current: 0.13
0.07
9.92
Price-to-Graham-Number 12.05
CORT's Price-to-Graham-Number is ranked lower than
92% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 2.69 vs. CORT: 12.05 )
Ranked among companies with meaningful Price-to-Graham-Number only.
CORT' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 9.55  Med: 11.77 Max: 23.74
Current: 12.05
9.55
23.74
Earnings Yield (Greenblatt) % 1.04
CORT's Earnings Yield (Greenblatt) % is ranked higher than
76% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.87 vs. CORT: 1.04 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CORT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -692.3  Med: -14.2 Max: 1.3
Current: 1.04
-692.3
1.3

More Statistics

Revenue (TTM) (Mil) $92.86
EPS (TTM) $ 0.11
Beta1.62
Short Percentage of Float9.37%
52-Week Range $4.95 - 12.57
Shares Outstanding (Mil)113.19
» More Articles for CORT

Headlines

Articles On GuruFocus.com
Corcept Therapeutics Appoints Renee D. Gala to Board of Directors Jun 28 2016 
Corcept Therapeutics Provides Update of Progress in Cortisol Modulation Oncology Program Jun 02 2016 
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host Confe Apr 29 2016 
Promising Pre-Clinical and Phase 1 Data Support Advance of Selective Cortisol Modulator CORT125134 a Apr 28 2016 
David Swensen Bets on Antero Resources Mar 10 2016 
Corcept Therapeutics Announces Preliminary Fourth Quarter and Full Year 2015 Summary Financial Resul Jan 28 2016 
Corcept Therapeutics to Announce Preliminary 2015 Financial Results, Provide 2016 Revenue Guidance a Jan 21 2016 
Corcept Therapeutics Announces Initial Efficacy Results in Phase 1/2 Trial of Mifepristone in Combin Dec 14 2015 
Corcept Therapeutics to Announce Third Quarter Financial Results and Corporate Update and Host Confe Oct 29 2015 
Results of Phase 1 Trial of Next-Generation Cortisol Modulator CORT125134 to Be Presented at Annual Oct 13 2015 

More From Other Websites
ETFs with exposure to Corcept Therapeutics, Inc. : June 19, 2017 Jun 19 2017
Corcept Therapeutics, Inc. :CORT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : June... Jun 15 2017
Pharma Stock With Triple-Digit Growth Forming Blotchy Base May 24 2017
ETFs with exposure to Corcept Therapeutics, Inc. : May 18, 2017 May 18 2017
Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium... May 12 2017
4 of the Cheapest Biotech Stocks in the World May 10 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CORT-US : May... May 10 2017
Edited Transcript of CORT earnings conference call or presentation 1-May-17 9:00pm GMT May 04 2017
Corcept Therapeutics Announces Presentations on Mifepristone for the Treatment of Patients with... May 04 2017
Corcept posts 1Q profit May 01 2017
Corcept Therapeutics Announces First Quarter 2017 Financial Results, Raises 2017 Revenue Guidance... May 01 2017
Investor Network: Corcept Therapeutics Incorporated. to Host Earnings Call May 01 2017
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View Apr 27 2017
Corcept Therapeutics, Inc. – Value Analysis (NASDAQ:CORT) : April 25, 2017 Apr 25 2017
Corcept Therapeutics to Announce First Quarter Financial Results and Corporate Update and Host... Apr 24 2017
Corcept Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CORT-US : April... Apr 24 2017
Here's Why Corecept Therapeutics Incorporated Had a Rough Day Apr 21 2017
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine Apr 20 2017
Corcept (CORT) Up 18% Since Earnings Report: Can It Continue? Apr 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}